TABLE OF CONTENTS
1 INTRODUCTION 67
1.1 OBJECTIVES OF THE STUDY 67
1.2 MARKET DEFINITION 67
1.3 OVERVIEW 67
1.4 CURRENCY AND PRICING 69
1.5 LIMITATIONS 69
1.6 MARKETS COVERED 70
2 MARKET SEGMENTATION 73
2.1 MARKETS COVERED 73
2.2 GEOGRAPHICAL SCOPE 74
2.3 YEARS CONSIDERED FOR THE STUDY 75
2.4 DBMR TRIPOD DATA VALIDATION MODEL 76
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 79
2.6 MULTIVARIATE MODELLING 80
2.7 MARKET APPLICATION COVERAGE GRID 81
2.8 PRODUCT LIFELINE CURVE 82
2.9 DBMR MARKET POSITION GRID 83
2.10 VENDOR SHARE ANALYSIS 85
2.11 SECONDARY SOURCES 86
2.12 ASSUMPTIONS 86
3 EXECUTIVE SUMMARY 87
4 PREMIUM INSIGHTS 90
4.1 PORTERS FIVE FORCES 91
4.2 PESTEL ANALYSIS 92
4.3 INDUSTRY INSIGHTS 93
4.4 CONCLUSION 94
5 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK 95
6 MARKET OVERVIEW 97
6.1 DRIVERS 99
6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER 99
6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS 99
6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES 100
6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES 100
6.2 RESTRAINTS 101
6.2.1 HIGH COST OF FISH TESTING 101
6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS 101
6.3 OPPORTUNITIES 102
6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES 102
6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES 102
6.4 CHALLENGES 103
6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES 103
6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY 103
7 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE 104
7.1 OVERVIEW 105
7.2 CONSUMABLES 108
7.2.1 FISH PROBE 108
7.2.1.1 FISH PROBE, BY PROBE TYPE 109
7.2.1.1.1 CHROMOSOME FISH PROBE 109
7.2.1.1.2 SPLIT FISH PROBES 109
7.2.1.1.3 TRANSLOCATION FISH PROBES 109
7.2.1.1.4 SUBTELOMERE FISH PROBES 109
7.2.1.1.5 PRENATAL FISH PROBES 109
7.2.1.1.6 OTHERS PROBES 110
7.2.1.2 FISH PROBE, BY TECHNOLOGY 110
7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION 110
7.2.1.2.2 C-ISH 110
7.2.1.2.3 D-ISH 110
7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION 110
7.2.1.2.5 OTHERS 110
7.2.1.3 FISH PROBE, BY TYPE 111
7.2.1.3.1 RNA 111
7.2.1.3.1.1 MRNA 111
7.2.1.3.1.2 MIRNA 111
7.2.1.3.1.3 OTHERS 112
7.2.1.3.2 DNA 112
7.2.2 ACCESSORY KITS & REAGENTS 112
7.2.2.1 KITS 112
7.2.2.2 BUFFER 112
7.2.2.3 DYES 112
7.2.2.4 OTHERS 113
7.3 INSTRUMENT 113
7.3.1 STANDALONE 114
7.3.2 PORTABLE 114
7.3.3 HANDHELD 114
7.4 SOFTWARE 114
8 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY 115
8.1 OVERVIEW 116
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION 119
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION 120
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION 121
8.5 OTHERS 122
9 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION 123
9.1 OVERVIEW 124
9.2 CANCER RESEARCH 127
9.2.1 CANCER RESEARCH, BY CANCER TYPE 128
9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) 128
9.2.1.1.1 BREAST CANCER 128
9.2.1.1.2 LUNG CANCER 128
9.2.1.1.3 MELANOMA 129
9.2.1.1.4 PROSTRATE CANCER 129
9.2.1.1.5 OVARIAN CANCER 129
9.2.1.1.6 OTHERS 129
9.2.1.2 HEMATOPOETIC MALIGNANCIES 129
9.2.1.2.1 LEUKEMIA 129
9.2.1.2.2 MULTIPLE MYELOMA 130
9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS) 130
9.2.2 CANCER RESEARCH, BY PRODUCT 130
9.2.2.1 CONSUMABLES 130
9.2.2.2 INSTRUMENTS 130
9.2.2.3 SOFTWARE 130
9.3 GENETIC RESEARCH 131
9.3.1 CYTOGENETICS 132
9.3.2 CHROMOSOMAL ABNORMALITIES 132
9.3.3 OTHERS 132
9.4 INFECTIOUS DISEASE 132
9.4.1 CONSUMABLES 133
9.4.2 INSTRUMENTS 133
9.4.3 SOFTWARE 133
9.5 PERSONALIZED MEDICINE 133
9.6 OTHERS 134
10 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE 135
10.1 OVERVIEW 136
10.2 RESEARCH 139
10.2.1 INSTRUMENTS 139
10.2.2 CONSUMABLES 140
10.2.3 SOFTWARE 140
10.3 CLINICAL 140
10.3.1 CONSUMABLES 141
10.3.2 INSTRUMENT 141
10.3.3 SOFTWARE 141
10.4 COMPANION DIAGNOSTIC 141
10.4.1 CONSUMABLES 142
10.4.2 INSTRUMENT 142
10.4.3 SOFTWARE 142
11 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER 143
11.1 OVERVIEW 144
11.2 DIAGNOSTIC LABORATORIES 147
11.3 HOSPITALS & CLINICS 147
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES 148
11.5 ACADEMIC & RESEARCH INSTITUTES 149
11.6 CONTRACT RESEARCH ORGANIZATIONS 149
11.7 OTHERS 150
12 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL 151
12.1 OVERVIEW 152
12.2 RETAIL SALES 155
12.3 ONLINE SALES 155
12.4 DIRECT TENDER 156
12.5 OTHERS 157
13 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION 158
13.1 MIDDLE EAST AND AFRICA 159
13.1.1 SOUTH AFRICA 173
13.1.2 SAUDI ARABIA 183
13.1.3 EGYPT 191
13.1.4 UAE 200
13.1.5 KUWAIT 208
13.1.6 QATAR 217
13.1.7 OMAN 225
13.1.8 BAHRAIN 234
13.1.9 REST OF MIDDLE EAST AND AFRICA 242
14 MIDDLE EAST & AFRICA FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE 243
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 243
15 SWOT ANALYSIS 244
16 COMPANY PROFILE 245
16.1 MERCK KGAA 245
16.1.1 COMPANY SNAPSHOT 245
16.1.2 REVENUE ANALYSIS 245
16.1.3 COMPANY SHARE ANALYSIS 246
16.1.4 PRODUCT PORTFOLIO 246
16.1.5 RECENT DEVELOPMENT 246
16.2 ABBOTT 247
16.2.1 COMPANY SNAPSHOT 247
16.2.2 REVENUE ANALYSIS 247
16.2.3 COMPANY SHARE ANALYSIS 248
16.2.4 PRODUCT PORTFOLIO 248
16.2.5 RECENT DEVELOPMENT 249
16.3 AGILENT TECHNOLOGIES, INC. 250
16.3.1 COMPANY SNAPSHOT 250
16.3.2 REVENUE ANALYSIS 250
16.3.3 COMPANY SHARE ANALYSIS 251
16.3.4 PRODUCT PORTFOLIO 251
16.3.5 RECENT DEVELOPMENT 251
16.4 F. HOFFMANN-LA ROCHE LTD. 252
16.4.1 COMPANY SNAPSHOT 252
16.4.2 REVENUE ANALYSIS 252
16.4.3 COMPANY SHARE ANALYSIS 253
16.4.4 PRODUCT PORTFOLIO 253
16.4.5 RECENT DEVELOPMENT 253
16.5 THERMO FISCHER SCIENTIFIC INC. 254
16.5.1 COMPANY SNAPSHOT 254
16.5.2 REVENUE ANALYSIS 254
16.5.3 COMPANY SHARE ANALYSIS 255
16.5.4 PRODUCT PORTFOLIO 255
16.5.5 RECENT DEVELOPMENT 256
16.6 ABCAM PLC. 257
16.6.1 COMPANY SNAPSHOT 257
16.6.2 REVENUE ANALYSIS 257
16.6.3 COMPANY SHARE ANALYSIS 258
16.6.4 PRODUCT PORTFOLIO 258
16.6.5 RECENT DEVELOPMENTS 258
16.7 ABNOVA CORPORATION 260
16.7.1 COMPANY SNAPSHOT 260
16.7.2 PRODUCT PORTFOLIO 260
16.7.3 RECENT DEVELOPMENT 260
16.8 BIO SB 261
16.8.1 COMPANY SNAPSHOT 261
16.8.2 PRODUCT PORTFOLIO 261
16.8.3 RECENT DEVELOPMENT 261
16.9 BIOCARE MEDICAL, LLC 262
16.9.1 COMPANY SNAPSHOT 262
16.9.2 PRODUCT PORTFOLIO 262
16.9.3 RECENT DEVELOPMENT 263
16.10 BIOCAT GMBH 264
16.10.1 COMPANY SNAPSHOT 264
16.10.2 PRODUCT PORTFOLIO 264
16.10.3 RECENT DEVELOPMENT 265
16.11 BIODOT 266
16.11.1 COMPANY SNAPSHOT 266
16.11.2 PRODUCT PORTFOLIO 266
16.11.3 RECENT DEVELOPMENT 266
16.12 BIOGENEX 267
16.12.1 COMPANY SNAPSHOT 267
16.12.2 PRODUCT PORTFOLIO 267
16.12.3 RECENT DEVELOPMENT 267
16.13 BIO-TECHNE 268
16.13.1 COMPANY SNAPSHOT 268
16.13.2 REVENUE ANALYSIS 268
16.13.3 COMPANY SHARE ANALYSIS 269
16.13.4 PRODUCT PORTFOLIO 269
16.13.5 RECENT DEVELOPMENT 269
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH 270
16.14.1 COMPANY SNAPSHOT 270
16.14.2 PRODUCT PORTFOLIO 270
16.14.3 RECENT DEVELOPMENT 271
16.15 EXCILONE 272
16.15.1 COMPANY SNAPSHOT 272
16.15.2 PRODUCT PORTFOLIO 272
16.15.3 RECENT DEVELOPMENT 272
16.16 GENEMED BIOTECHNOLOGIES, INC. 273
16.16.1 COMPANY SNAPSHOT 273
16.16.2 PRODUCT PORTFOLIO 273
16.16.3 RECENT DEVELOPMENT 273
16.17 KANEKA EUROGENTEC S.A. 274
16.17.1 COMPANY SNAPSHOT 274
16.17.2 PRODUCT PORTFOLIO 274
16.17.3 RECENT DEVELOPMENT 274
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH 275
16.18.1 COMPANY SNAPSHOT 275
16.18.2 PRODUCT PORTFOLIO 275
16.18.3 RECENT DEVELOPMENT 275
16.19 METASYSTEMS 276
16.19.1 COMPANY SNAPSHOT 276
16.19.2 PRODUCT PORTFOLIO 276
16.19.3 RECENT DEVELOPMENT 276
16.20 SYSMEX ASIA PACIFIC PTE LTD (A SUBSIDIARY OF SYSMEX CORPORATION) 277
16.20.1 COMPANY SNAPSHOT 277
16.20.2 REVENUE ANALYSIS 277
16.20.3 PRODUCT PORTFOLIO 278
16.20.4 RECENT DEVELOPMENT 278

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.